Madaus Gmbh

Euromed S.a.

Ralf-Torsten Pohl

Lucio C Rovati

Ulrich Mengs

Massimo Maria D'Amato

Peter Ferenci

Astrid Nagell

Aguirre Jaime Xiol

Prous Santiago Rull

Lucio Claudio Rovati

Massimo Maria D'amato

The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.

Silibinin component for the treatment of hepatitis

The invention relates to a method for the preparation of amorphous silibinin (or its synonyms: silybin or silibin) derived from a milk thistle fruit extract having an increased release rate and improved absorbability or bioavailability, and to the use of amorphous silibinin for the treatment or prevention of liver diseases, preferably for the treatment of viral hepatitis, e.g. hepatitis B or C, in particular in a patient who will undergo or has undergone liver transplantation. Preferably, the amorphous silibinin is adapted for oral administration.

Amorphous silibinin for the treatment of viral hepatitis

Growing community of inventors

Speyer, Germany

Ralf-Torsten Pohl